poisar

Stocks · News reference

iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial

Jun 2, 2026, 11:04 AMBenzinga Newsdesk

iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IBIO
Source
benzinga
Observed
Jun 2, 2026, 11:04 AM
Checked
Jun 2, 2026, 11:05 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 4, 2026, 11:05 AMSEC EDGAR

    8-K filing — iBio, Inc. (IBIO)

    Filed: 2026-08-04 AccNo: 0001420720-26-000014 Size: 287 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    IBIO